Multiple Sclerosis (MS) is a chronic inflammatory, neurodegenerative disease. Diagnosis is very difficult requiring defined symptoms and multiple CNS imaging. A complicating issue is that almost all symptoms are not disease specific for MS. Autoimmunity is evident, yet the only immune-related diagnostic tool is cerebral-spinal fluid examination for oligoclonal bands. This study addresses the impact of Th40 cells, a pathogenic effector subset of helper T cells, in MS. MS patients including relapsing/remitting MS, secondary progressive MS and primary progressive MS were examined for Th40 cell levels in peripheral blood and, similar to our findings in autoimmune type 1 diabetes, the levels were significantly (p b 0.0001) elevated compared to controls including healthy non-autoimmune subjects and another non-autoimmune chronic disease. Classically identified Tregs were at levels equivalent to non-autoimmune controls but the Th40/Treg ratio still predicted autoimmunity. The cohort displayed a wide range of HLA haplotypes including the GWAS identified predictive HLA-DRB1*1501 (DR2). However half the subjects did not carry DR2 and regardless of HLA haplotype, Th40 cells were expanded during disease. In RRMS Th40 cells demonstrated a limited TCR clonality. Mechanistically, Th40 cells demonstrated a wide array of response to CNS associated self-antigens that was dependent upon HLA haplotype. Th40 cells were predominantly memory phenotype producing IL-17 and IFNγ with a significant portion producing both inflammatory cytokines simultaneously suggesting an intermediary between Th1 and Th17 phenotypes.
Introduction
Multiple Sclerosis (MS) is a complex neurodegenerative disease. Multifocal lesions are present in the brain and spinal cord, predominantly in white matter although gray matter infiltrates are detected (Lucchinetti et al., 2011) . The disease has multifactorial, yet unresolved etiology with genetic, immunologic and environmental factors each presumed contributors. The most common disease course is relapsing/ remitting multiple sclerosis (RRMS) accounting for 85% of cases with more than 50% of those eventually becoming secondary progressive (SPMS), a more severe course of disease (Hemmer et al., 2002) . RRMS patients have CNS lesions characterized by edema and demyelination resulting from an inflammatory process (Miller et al., 1998) ; in 82% of lesions, CD3 + T cell infiltrates were detected (Lucchinetti et al., 2011) .
Findings suggest that inflammation mediated by immune activation is prevalent early, an attribute that is consistent with progressive autoimmunity. Diagnosis of MS is relatively complicated. A wide range of symptoms including: blurred or tunnel vision, general weakness, numbness, prickling pain, muscle spasm(s), tremors, dizziness, headaches, paraparesis, memory loss, speech impediment, attention deficit, decreased concentration etc., are associated with the disease. However these symptoms are likewise associated with other neurologic disorders (OND) and diverse diseases such as vascular diseases, infectious diseases, vitamin B-12 deficiency, hypo-thyroidism and even brain tumors. In order to diagnose MS disease, criteria were defined by what came to be known as the McDonald criteria, which were revised in 2005 (Polman et al., 2005) and again in 2010 (Polman et al., 2011) . The revised criteria require clinical and para-clinical laboratory assessments e.g. composite symptoms with MRI and spinal taps, etc., with demonstrated dissemination of lesions (MRI) in space (DIS) and time (DIT) (Polman et al., 2011) . The new criteria however do not advance understanding of the autoimmune contributors to MS. Even with the changes to the McDonald criteria it "remains imperative that alternative diagnoses are considered and excluded" (Polman et al., 2011) . The International Panel on Diagnosis of MS stressed that the McDonald criteria "should only be applied in those patients who present with a typical clinically isolated syndrome (CIS) suggestive of MS or symptoms consistent with a CNS inflammatory demyelinating disease" (Polman et al., 2011) . CIS can include optic neuritis, brainstem or spinal cord syndromes. While these often are the first clinical presentations of MS, not all CIS patients develop MS, for example in one longitudinal
